Wave Life Sciences announced positive interim data from its FORWARD-53 trial of WVE-N531 in Duchenne Muscular Dystrophy (DMD) patients amenable to exon 53 skipping.
A post-hoc analysis of a Phase 2 trial reveals that RNS60, when added to standard ALS therapies, extends median survival by approximately six months compared to placebo.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.